eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


3/2023
vol. 22
 
Share:
Share:
Review paper

A rare case of squamous cell carcinoma associated with a huge ovarian dermoid cyst in a postmenopausal woman

Shabnam K
1
,
Jasmina Begum
1

  1. All India Institute of Medical Sciences, Bhubaneswar, India
Menopause Rev 2023; 22(3): 169-172
Online publish date: 2023/09/25
Article file
Get citation
 
PlumX metrics:
 

Introduction

Ovarian malignancies are India’s second most common gynecological malignancy next to cervical malignancy. A varied and nonspecific presentation and a lack of screening make early diagnosis difficult. Most ovarian malignancies are often diagnosed in advanced stages. Mature cystic teratoma (MCT) of the ovary accounts for 10–20% of all ovarian neoplasms and is most commonly seen in women of reproductive age group and less commonly in postmenopausal women [1]. Mature cystic teratoma is a germ cell tumor of the ovary and histologically consists of tissues arising from endoderm, mesoderm, and ectoderm. A malignant tumor transformation is a rare event that accounts for only 1–2% of cases, with squamous cell carcinoma (SCC) accounting for up to 80% of all cases [1, 2]. It is derived from the ectoderm component of mature teratoma of the ovary. Pure primary squamous cell carcinoma, occurring de novo, is rare. Patients may present with abdominal pain, distension of the abdomen, or mass per abdomen. Either way, as only parts of the lesion are composed of malignant transformation, preoperative diagnosis of the malignancy is difficult. We report here a case of SCC in a postmenopausal woman associated with a large ovarian dermoid cyst.

Ethical approval

The study was completely explained to the patient and performed in accordance with the principles of the Declaration of Helsinki. Written informed consent is attached. The patient provided written informed consent for the publication and use of her images.

Case report

Mrs. X, a 65-year-old P4L4 woman, presented to us with complaints of intermittent lower abdominal pain for 6 months. An abdominopelvic mass corresponding to a 24 weeks gravid uterus was felt on examination. The mass was firm-cystic, had regular margins, and was mobile sideways. The patient was evaluated and was found to have hypothyroidism. We did a pap smear as she had not undergone any prior cervical cancer screening over the last 15 years. Her pap smear revealed a low-grade squamous intraepithelial lesion. Ultrasonography revealed a well-defined heterogenous lesion measuring 10.5 × 19.0 × 14.1 cm with typical features of a dermoid cyst likely arising from the right ovary (Fig. 1). Contrast enhanced computed tomography of the abdomen and pelvis confirmed the ultrasound finding as an ovarian dermoid cyst probably arising from the right ovary measuring 14.7 × 16.3 × 18.3 cm. No metastatic deposits were detected anywhere in the abdomen and pelvis, nor were there any lymph node enlargements. Her tumor marker CA125 level was normal. Intraoperatively a dermoid cyst of 20 × 15 cm was seen arising from the right ovary; around 15 ml of blood-stained ascitic fluid was present, which was sent for cytology, and no peritoneal deposit was noted anywhere in the peritoneal cavity (Fig. 2). She underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy. The postoperative period was uneventful, and the patient was discharged. On follow-up, the histopathology report revealed a right ovarian dermoid cyst with well-differentiated SCC confined to the cyst wall; there was no evidence of malignancy elsewhere, including the cervix (Figs. 3, 4). Ascitic fluid was also free of malignant cells, and the disease was at stage Ia. The patient did not receive any adjuvant chemotherapy and was followed up with clinical examination postoperatively for 1 year, and there was no evidence of any relapse clinically. This case is being reported with the consent of the patient.

Fig. 1

Transabdominal ultrasound image showing huge cyst with (A) multiple thin, echogenic bands caused by the hair in the cyst cavity the dash-dot pattern (dermoid mesh), and (B) mural hyperechoic Rokitansky nodule (dermoid plug), likely dermoid cyst

/f/fulltexts/PM/51467/MR-22-51467-g001_min.jpg
Fig. 2

Intraoperative appearance of the huge cyst

/f/fulltexts/PM/51467/MR-22-51467-g002_min.jpg
Fig. 3

Section from the ovarian cyst shows stratified squamous epithelium and a thin fibro-collagenous wall (H&E stain, 100×)

/f/fulltexts/PM/51467/MR-22-51467-g003_min.jpg
Fig. 4

Thickened areas of the cyst showed features of welldifferentiated squamous cell carcinoma and keratin pearls (H&E stain, 200×)

/f/fulltexts/PM/51467/MR-22-51467-g004_min.jpg

Discussion

Although benign MCT is a tumor of the reproductive age group and a malignant transformation is rare, it often occurs in postmenopausal women. The most common subtype is SCC. Squamous cell carcinoma occurring de novo is even rarer. Malignant transformation is derived from the ectoderm component of mature teratoma of the ovary.

A possible causal relationship between primary ovarian SCC and human papillomavirus (HPV) has been explored in recent times [3, 4]. Human papillomavirus is known to cause invasive SCC of the cervix. The incidence of cervix SCC has come down due to increased availability and prompt screening with a pap smear, HPV tests, colposcopy, etc. However, there has been a recent rise in cases of cervical adenocarcinoma. A pap smear is primarily a screening test for SCC of the cervix. The presence of exfoliated endometrial cells can be normal during menstruation and in the proliferative phase of the menstrual cycle in reproductive age. But the presence of these cells in postmenopausal women requires further evaluation to rule out endometrial cancer or cervical adenocarcinoma. All women with atypical endometrial cells on Pap tests need endocervical curettage and endometrial sampling to rule out malignancy from an endometrial cavity or endocervical canal [5]. It is also important to differentiate adenocarcinoma of the cervix from that of the endometrium as they may have similar presentations, but the management is different.

Squamous cell carcinoma, either primary or secondary to malignant transformation, may present with abdominal pain, distension of the abdomen, abdominal mass, etc. There may also be associated pressure symptoms. As with any such clinical presentation, further workup in the form of ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) may be warranted on a case-to-case basis. Not only does it help in knowing the origin and nature of the tumor, but also it differentiates it from uterine tumors. It will also help to differentiate a probable benign lesion from a malignant one. In the case of uterine tumors at an older age, postmenopausal bleeding is the most common symptom at presentation; no matter how minimal or nonpersistent, it needs evaluation. Transvaginal sonography with color Doppler is an efficient and acceptable non-invasive method for the early detection of endometrial pathologies with a sensitivity of 97% and a specificity of 74% [6]. On detection of suspected endometrial abnormalities, the next step is to evaluate with hysteroscopic directed endometrial biopsy. It has 100% sensitivity and 97% specificity for the detection of endometrial cancer [6]. The rare gynecologic malignancy uterine sarcoma is diagnosed by the history of rapid growth, postmenopausal bleeding, and ultrasonographic findings of solid masses in the uterus with heterogeneous echogenicity and well-enhanced vascularity. Sometimes, very rarely, it can be diagnosed in endometrial biopsy when it spreads to the inner lining of the uterus. Evaluation of huge masses is difficult by ultrasound; the most preferred techniques are CT and MRI. This will confirm the diagnosis, differentiate benign from malignant masses, and also provides information regarding the extension and metastasis of malignant masses [7]. In our case, radiologically the appearance was identical to that often seen in cases of benign mature ovarian teratoma. As only parts of the lesion are composed of malignant tissue and symptoms are primarily nonspecific, it is difficult to diagnose the malignant transformation of a teratoma preoperatively unless invasion into adjacent structures is present. However, in the absence of evident tumor invasion or metastases, it may be challenging to preoperatively identify an aggressive component in ovarian teratomas due to their heterogeneity.

Various tumor markers have proven diagnostic and prognostic roles in different gynecological malignancies. A raised level of cancer antigen 125 (CA 125) ≥ 35 IU/ml supports the diagnosis of serous epithelial ovarian cancers. It is a strong prognostic factor for the overall survival and progression-free survival of ovarian tumors [7]. Carbohydrate antigen 19-9 (C19.9) is found raised in mucinous epithelial ovarian cancers and also in malignant hepatobiliary and pancreatic conditions. Carcinoembryonic antigen (CEA) levels may also be raised in epithelial ovarian malignancies. As of yet, no single tumor marker is thought to be best in the diagnosis of SCC in the ovary, but CEA appears to be the best screening marker for SCC arising from mature cystic teratoma, better than CA125 or CA 19.9, but this requires further research [8, 9]. Overall, elderly age at presentation, huge tumor size, and large solid components, especially if irregular in the tumor, are important predictive factors for malignant transformation [8].

There is no specific treatment protocol for SCC in the ovary. However, a mixture of surgery plus chemotherapy and radiotherapy may be tried depending on the stage, grade, and parity of the tumor. Unilateral oophorectomy is performed in a nulliparous or young woman where fertility is an issue with stage IA disease. In postmenopausal women, the treatment of choice would be a total abdominal hysterectomy with bilateral oophorectomy [10]. No consensus or standard guidelines are available regarding the optimum outcome of post-operative adjuvant management of SCC arising from MCT because of a relatively little known entity and limited studies. A systematic review carried out by Hackethal et al. stressed a high survival rate associated with complete resection of the tumor followed by adjuvant chemotherapy based on alkylating agents in advanced disease. The study showed a higher overall survival rate of 57.1 months when alkylating agents were administered compared to 25.2 months for those who received non-alkylating regimens [11]. Although the prognosis in the case of malignant transformation is poor, the earlier stage of the disease limited to the ovary shows a better prognosis compared to the advanced stage [12]. Squamous cell carcinoma arising from MCT poses diagnostic as well as therapeutic challenges, and more research is needed to reach a consensus for the treatment protocol.

Conclusions

Squamous cell carcinoma in the ovary is rare. It occurs primarily associated with a dermoid cyst or endometriosis and rarely arises de novo. Preoperative diagnosis is difficult and lacks specific screening markers or a treatment protocol, so more cases must be studied to reach a consensus for treating such cases. Considering the scarcity of case reports and studies about SCC arising from MCT, every experience with malignant transformation of MCT should be reported for a better understanding of the disease presentation and management.

Acknowledgments

We are grateful to the patients for the consent to report the case history. We would also like to thank our colleagues in the Department of Pathology, for providing us with histopathology photomicrographs.

Disclosure

The authors report no conflict of interest.

References

1 

Li C, Zhang Q, Zhang S, et al. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review. BMC Cancer 2019; 19: 217.

2 

Zubair M, Hashmi SN, Afzal S, Muhammad I, Ud Din H, Hamdani SN. Squamous cell carcinoma arising in background of mature cystic teratoma. J Coll Physicians Surg Pak 2016; 26: 929-930.

3 

Mai KT, Yazdi HM, Bertrand MA, LeSaux N, Cathcart LL. Bilateral primary ovarian squamous cell carcinoma associated with human papillomavirus infection and vulvar and cervical intraepithelial neoplasia. A case report with a review of the literature. Am J Surg Pathol 1996; 20: 767-772.

4 

Manolitsas TP, Lanham SA, Hitchcock A, Watson RH. Synchronous ovarian and cervical squamous intraepithelial neoplasia: an analysis of HPV status. Gynecol Oncol 1998; 70: 428-431.

5 

Nadaf A, Rani H, S S P, Rao R, Shastri D. Pap smears in endometrial adenocarcinoma: does it have a role? Asian Pac J Cancer Prev 2017; 18: 1145-1150.

6 

Mulita F, Liolis E, Kehagias D, et al. An enormous pelvic tumor in a 46-year-old woman with an elevated serum CA 125 level, what lies beneath it? Investigation of uterine tumors in postmenopausal women. Prz Menopauz 2021; 20: 154-157.

7 

Mulita F, Tavlas P, Maroulis I. A giant ovarian mass in a 68-year-old female with persistent abdominal pain and elevated serum CA-125 level. Prz Menopauz 2020; 19: 108-110.

8 

Kikkawa F, Ishikawa H, Tamakoshi K, Nawa A, Suganuma N, Tomoda Y. Squamous cell carcinoma arising from mature cystic teratoma of the ovary: a clinicopathologic analysis. Obstet Gynecol 1997; 89: 1017-1022.

9 

Mulita F, Oikonomou N, Tchabashvili L, Liolis E, Kehagias I. A giant ovarian mucinous tumor in a 58-year-old postmenopausal patient with persistent abdominal pain and high serum levels of CA 19-9. Pan Afr Med J 2020; 37: 76.

10 

Maharjan S. Mature cystic teratoma of ovary with squamous cell carcinoma arising from it. Clin Case Rep 2019; 7: 668-671.

11 

Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg HR, Münstedt K. Squamous cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol 2008; 9: 1173-1180.

12 

Zhang C, Ma T. Poorer prognosis of ovarian squamous cell carcinoma than serous carcinoma: a propensity score matching analysis based on the SEER database. J Ovarian Res 2020; 13: 75.

Copyright: © 2023 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.